111 155

Cited 8 times in

Therapeutic efficacy of chloroquine in Plasmodium vivax and the pvmdr1 polymorphisms in the Republic of Korea under mass chemoprophylaxis.

DC FieldValueLanguage
dc.contributor.author김준명-
dc.contributor.author김창수-
dc.contributor.author최준용-
dc.date.accessioned2014-12-20T16:26:22Z-
dc.date.available2014-12-20T16:26:22Z-
dc.date.issued2011-
dc.identifier.issn0002-9637-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/92718-
dc.description.abstractChemoprophylaxis with hydroxychloroquine (HCQ) and primaquine has been used in the Republic of Korea (ROK) Army since 1997. It may facilitate the development of chloroquine (CQ)-resistant strains of Plasmodium vivax. We investigated the therapeutic efficacy of HCQ and the pvmdr1 gene polymorphisms in P. vivax. From June to September 2006, 102 soldiers with vivax malaria near the demilitarized zone in Gyeonggi-do, ROK, were enrolled in the study. We determined the status of compliance of chemoprophylaxis. In 85 patients, therapeutic efficacy was monitored 28 days after standard HCQ treatment; 66 (64.7%) of 102 malaria patients had taken all chemoprolaxis with HCQ. In all patients enrolled in the therapeutic efficacy monitoring, parasitemia had not been observed since 3 days after standard HCQ treatment. However, the ubiquitous presence of the F1076L mutation of the pvmdr1 was observed. There was no evidence that the F1076L mutation of pvmdr1 could contribute to failure of HCQ treatment-
dc.description.statementOfResponsibilityopen-
dc.format.extent532~534-
dc.relation.isPartOfAmerican Journal of Tropical Medicine and Hygiene-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/2.0/kr/-
dc.subject.MESHAntimalarials/blood-
dc.subject.MESHAntimalarials/pharmacology-
dc.subject.MESHAntimalarials/therapeutic use*-
dc.subject.MESHChloroquine/blood-
dc.subject.MESHChloroquine/pharmacology*-
dc.subject.MESHChloroquine/therapeutic use-
dc.subject.MESHDrug Resistance/genetics-
dc.subject.MESHHumans-
dc.subject.MESHHydroxychloroquine/therapeutic use-
dc.subject.MESHMalaria, Vivax/drug therapy-
dc.subject.MESHMalaria, Vivax/epidemiology*-
dc.subject.MESHMalaria, Vivax/parasitology-
dc.subject.MESHMultidrug Resistance-Associated Proteins/genetics*-
dc.subject.MESHPlasmodium vivax/drug effects*-
dc.subject.MESHPlasmodium vivax/genetics-
dc.subject.MESHPolymorphism, Genetic*-
dc.subject.MESHPrimaquine/therapeutic use-
dc.subject.MESHProtozoan Proteins/genetics*-
dc.subject.MESHRepublic of Korea/epidemiology-
dc.titleTherapeutic efficacy of chloroquine in Plasmodium vivax and the pvmdr1 polymorphisms in the Republic of Korea under mass chemoprophylaxis.-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Internal Medicine (내과학)-
dc.contributor.googleauthorYoung Keun Kim-
dc.contributor.googleauthorChangsoo Kim-
dc.contributor.googleauthorInho Park-
dc.contributor.googleauthorHyo Youl Kim-
dc.contributor.googleauthorJun Yong Choi-
dc.contributor.googleauthorJune Myung Kim-
dc.identifier.doi10.4269/ajtmh.2011.10-0486-
dc.admin.authorfalse-
dc.admin.mappingfalse-
dc.contributor.localIdA00953-
dc.contributor.localIdA01042-
dc.contributor.localIdA04191-
dc.relation.journalcodeJ00122-
dc.identifier.pmid21460004-
dc.contributor.alternativeNameKim, June Myung-
dc.contributor.alternativeNameKim, Chang Soo-
dc.contributor.alternativeNameChoi, Jun Yong-
dc.contributor.affiliatedAuthorKim, June Myung-
dc.contributor.affiliatedAuthorKim, Chang Soo-
dc.contributor.affiliatedAuthorChoi, Jun Yong-
dc.rights.accessRightsfree-
dc.citation.volume84-
dc.citation.number4-
dc.citation.startPage532-
dc.citation.endPage534-
dc.identifier.bibliographicCitationAmerican Journal of Tropical Medicine and Hygiene, Vol.84(4) : 532-534, 2011-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Preventive Medicine and Public Health (예방의학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.